fluorouracil has been researched along with binimetinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L | 1 |
| Christy-Bittel, J; Ciardiello, F; Cuyle, PJ; Desai, J; Elez, E; Fakih, M; Gollerkeri, A; Grothey, A; Huijberts, S; Kopetz, S; Maharry, K; Montagut, C; Peeters, M; Sandor, V; Schellens, JHM; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y | 1 |
| Goi, T; Hirono, Y; Koneri, K; Kurebayashi, H; Morikawa, M; Murakami, M; Sakamoto, S; Sawai, K; Shimada, M; Tagai, N; Tamaki, M | 1 |
| Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K | 1 |
1 trial(s) available for fluorouracil and binimetinib
| Article | Year |
|---|---|
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Rate | 2019 |
4 other study(ies) available for fluorouracil and binimetinib
| Article | Year |
|---|---|
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Trifluridine | 2017 |
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sulfonamides; United States | 2021 |
[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Dermatitis; Female; Fluorouracil; Humans; Liver Neoplasms; Mutation; Proto-Oncogene Proteins B-raf | 2022 |
[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Retinal Detachment | 2022 |